Lunger John's Form 4 filing
Adaptimmune Therapeutics PLC (ADAPY) · filed Aug 1, 2023
- Accession no.
- 0001104659-23-086416
- Filed
- Aug 1, 2023
- Trade date
- Aug 1, 2023
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market sales total $2.82K. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lunger JohnCIK 0001784487 | Officer (Chief Patient Supply Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 1, 2023 | American Depositary Shares representing Ordinary Shares | SSaleDisposed | −3,096 | $0.91F2 | −$2,817.36 | 4,718 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is the sale price per ADS.
Referenced by the price of 1 transaction in Table I.